Talaris Therapeutics

$2.90 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Talaris Therapeutics

Talaris Therapeutics, Inc. operates as a biotechnology company. The Company focuses on developing proprietary method of allogeneic hematopoietic stem cell transplantation for chronic immunosuppression and treat patients who suffer from autoimmune diseases and non-malignant blood, immune, and metabolic disorders. Talaris Therapeutics serves patients in the United States.

Stock Analysis

last close $2.3
1-mo return -73.6%
3-mo return -75.9%
avg daily vol. 285.12T
52-week high 17.48
52-week low 2.04
market cap. $95M
forward pe -
annual div. -
roe -64.6%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 79%
baraka

Subscribe now for daily local and international financial news

Subscribe